Dose limiting toxicities

Related by string. dose limiting toxicities * DO Se . Doses . DOSE . DOSES : mg kg dose . label dose escalation . tolerated dose MTD . dose escalation study / limited . limits . Limits . Limiting : Limited Brands Inc. . Holdings Limited . Flow Through Limited . Limited Late Model / Toxicities : ERBITUX dermatologic toxicities . hematologic toxicities . non hematological toxicities * *

Related by context. Frequent words. (Click for all words.) 70 neutropenia thrombocytopenia 67 hematologic toxicity 65 Exclusion criteria 64 lymphopenia 64 laboratory abnormalities 63 bone marrow suppression 61 sensory neuropathy 61 diarrhea nausea vomiting 60 corticosteroid therapy 60 hypocalcemia 60 Adverse events 59 neurologic symptoms 59 mg kg dose 58 severe neutropenia 58 nephrotoxicity 57 myelosuppression 57 concomitant medications 57 DOXIL 57 ethambutol 57 unknown etiology 56 Severe infusion 56 metabolic acidosis 56 tumor lysis syndrome 56 TYSABRI treated 56 adrenal insufficiency 56 intramuscularly 56 55 Postoperative 55 posttreatment 55 #mg/m# [002] 55 μg kg 55 blebs 55 virological failure 55 sulfasalazine 55 Allergic reactions 55 COPD exacerbations 55 patients evaluable 55 lopinavir r arm 55 extrapyramidal symptoms 55 lactulose 55 clinically meaningful improvement 55 status epilepticus 54 hepatic failure 54 Secondary endpoints 54 adenotonsillectomy 54 PREZISTA r 54 HBeAg positive 54 events AEs 54 methylprednisolone 54 SAEs 53 treatment emergent adverse 53 lipid lowering agents 53 liver biopsies 53 gout flares 53 % CI #.#-#.# [007] 53 cytogenetic response 53 Withdrawal symptoms 53 fibrinolysis 53 imipenem 53 haematological 53 coagulopathy 53 Psoriasis Area 52 plus methotrexate 52 androgen deprivation 52 #mg/kg [002] 52 virologic failure 52 paroxysmal nocturnal hemoglobinuria 52 immunostaining 52 renal insufficiency 52 #mg/day [001] 52 ascending doses 52 splenic 52 3mg 52 anticholinergics 52 hematologic 52 heavily pretreated patients 52 MACCE 52 5-FU/LV 52 univariate analysis 52 chest radiograph 52 hypoglycemic events 52 adverse reactions incidence 52 phlebitis 52 hepatocellular 52 onsets 52 Traficet EN 52 DMSA 52 cerebrovascular accident 52 etiologies 52 inattention hyperactivity 51 docetaxel chemotherapy 51 % CI #.#-#.# [003] 51 discontinuations due 51 neoplasms 51 thyroid dysfunction 51 evaluable 51 P = .# 51 Ischemic 51 mg QD 51 daunorubicin 51 CIMZIA TM

Back to home page